AgelessRx vs Framework
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
AgelessRx
Best for longevity-focused GLP-1 care (pending verification)Starting at $199/mo
Framework
Best for Cost-sensitive patients who want the most aggressive entry-tier pricing ($25/week ~ $100/mo) with a named 503B FDA-registered pharmacy partner (The Pharmacy Hub) and no membership fees, who are comfortable with limited public disclosure on states served and corporate-entity attribution.Starting at $100/mo
Side-by-Side Comparison
| Feature | AgelessRx | Framework |
|---|---|---|
| Overall Score | ✓7.1/10 | 6.5/10 |
| Starting Price | $199/mo | ✓$100/mo |
| Editorial Rating | ✓3.6 ★ /5 | 3.3 ★ /5 |
| Features | 6 features | ✓10 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
AgelessRx
Pros
- ✓Established brand based in Ann Arbor, MI with US-licensed providers
- ✓Offers both compounded and brand-name (Wegovy) options
- ✓Longevity-first positioning — patients get a broader metabolic health framing vs single-condition GLP-1 funnels
- ✓Listed in both competitor directories
Cons
- ✗Stub entry — pricing, states served, and GLP-1-specific intake workflow need YMYL verification
- ✗Confidence LOW until verified
- ✗Longevity-first positioning means GLP-1 is one of several products — patients looking specifically for GLP-1 care may be funneled into a broader longevity intake
Framework
Pros
- ✓**Named 503B pharmacy partner (The Pharmacy Hub) explicitly disclosed** — uncommon in the WLR directory. 503B is the FDA-registered outsourcing facility pathway (distinct from 503A patient-specific compounding) and represents a different regulatory + quality-control framework.
- ✓Verbatim FDA compounded-medication disclaimer published — meets WLR transparency standard
- ✓'$25/week' pricing (~$100/mo) is among the most aggressive in the directory
- ✓$0 membership fees — no annual or platform fee structure
- ✓Phone support published with toll-free number (888) 412-0666
- ✓Personalized-plan positioning differentiates from one-size-fits-all marketplace platforms
Cons
- ✗LegitScript ID / certification NOT disclosed on the homepage
- ✗Specific states-served list NOT publicly disclosed
- ✗Named medical director / clinical leadership NOT disclosed
- ✗Corporate legal entity (LLC/Inc/PC) NOT disclosed (no footer copyright designation visible)
- ✗Governing law / arbitration venue NOT publicly stated
- ✗Refund / cancellation policy NOT publicly detailed
- ✗Per-dose pricing tier structure NOT explicitly disclosed (only 'as low as $25/week' starting tier)
- ✗$25/week framing requires unit conversion (~$100/mo at 4 weeks; ~$108/mo at 52-week annual average) — direct monthly-cost comparison less clear than competitors using $/mo framing
- ✗503B FDA-registered pathway has different supply-chain economics than 503A — patients should verify whether their specific medication is dispensed from The Pharmacy Hub or a different 503A subcontractor
Our Verdict
AgelessRx edges out Framework with a higher overall score of 7.1/10 and is particularly strong for longevity-focused GLP-1 care (pending verification). Framework remains a solid alternative, especially if you're looking for Cost-sensitive patients who want the most aggressive entry-tier pricing ($25/week ~ $100/mo) with a named 503B FDA-registered pharmacy partner (The Pharmacy Hub) and no membership fees, who are comfortable with limited public disclosure on states served and corporate-entity attribution..
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.